Gemfibrozil Tablets600 mg / 60 Count
Back to Products
Brand name: Lopid®
Indications and Usage:
Gemfibrozil tablets, USP are indicated as adjunctive therapy to diet for:
1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.
2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides.
THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL TABLETS, USP ARE ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY.
For more information please see the prescribing information.
For more information please see the prescribing information on DailyMed.
|White to off-white
|Free from Gluten
|Free from Sweeteners
|Free from Soy
|Free from Gelatin
|Contains Corn Starch
|Other Product Info
Calcium stearate, colloidal silicon dioxide, hypromellose, low substituted hydroxypropyl cellulose, low viscosity hydroxypropyl cellulose, microcrystalline cellulose, polyethylene glycol, polysorbate, pregelatinized starch (maize), and titanium dioxide.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and humidity.
|Product Shelf Life
*The brand names listed are not owned by Rising Pharma. Rising Pharma products are generic equivalents to the respective brand names listed on this website.